(Q38204468)

English

Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".

scientific article published on 14 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

E J Gane

1

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

K Agarwal

2

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

language of work or name

0 references

publication date

14 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

American Journal of Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

994-1002

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Global epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States☆☆☆

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Changing trends in hepatitis C-related mortality in the United States, 1995-2004.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Projecting future complications of chronic hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Global challenges in liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Hepatitis C virus kinetics during and immediately after liver transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

A longitudinal analysis of hepatitis C virus replication following liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

The association between hepatitis C infection and survival after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Recurrent and new hepatitis C virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Long-term outcome of hepatitis C infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Faldaprevir and deleobuvir for HCV genotype 1 infection.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis.

1 reference

https://api.crossref.org/works/10.1111%2FAJT.12714

21 January 2018

Identifiers

10.1111/AJT.12714

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38204468&oldid=2136528168"